Leading Prostate Cancer Expert Dr Daniel Danila Appointed Scientific Adviser

GUILDFORD, England, July 8, 2015 /PRNewswire/ -- ANGLE plc (AIM: AGLOTCQX: ANPCY), the specialist medtech company with pioneering products for cancer diagnostics, is pleased to announce the appointment of Daniel Costin Danila, MD, as a Scientific Advisor to the Company with immediate effect.

Dr Danila is a leader in the development and adoption of CTCs as predictive biomarkers to help clinicians select appropriate treatments.

He is an assistant attending physician at Memorial Hospital Cancer Center in New York as well as an instructor with the Weill Cornell Medical College.  Dr Danila's primary research focuses on prostate cancer.  Specifically, he is exploring a hypothesis that molecular profiling of circulating tumour cells (CTCs) can be used to assess biological determinants of the growth of prostate cancer tumours.

Most recently, Dr Danila served as the principal investigator (PI) for "Circulating Tumor Cells as Biomarkers for Patients with Metastatic Prostate Cancer: Developing Assays for Androgen Receptor Signaling Pathway", which focused on analysing CTCs from patients with metastatic prostate cancer for molecular biomarkers predictive of tumor sensitivity to targeted treatments.  Funding for the research was provided by the Department of Defense Congressionally Directed Medical Research Programs, Prostate Cancer Research Program, Physician Research Training Award.

Dr Danila received his MD from Carol Davila University of Medicine and Pharmacy in Bucharest, Romania and was a research fellow, intern and resident at Massachusetts General Hospital prior to joining Memorial Sloan Kettering Cancer Center in 2005.

ANGLE Founder and Chief Executive, Andrew Newland, commented:
"Dr Danila is a leader at Memorial Sloan Kettering, one of the world's top cancer centres, in the adoption of CTCs in clinical practice particularly in relation to prostate cancer, the second most common cancer for men.  Following our recent encouraging results in prostate cancer, we are delighted that Dr Danila will be working with us to bring this potential to patients."

Dr Daniel Danila, assistant attending physician at Memorial Hospital Cancer Center in New York and instructor with the Weill Cornell Medical College added:
"I am delighted to be joining ANGLE as a Scientific Advisor.  Developing predictive biomarkers of tumor sensitivity to better help clinicians in selecting the right treatment for patients at the time of treatment decision is a key unmet need.  Molecular profiling of CTCs holds the promise of sampling the tumor tissue with the convenience of a simple blood test.  Novel enrichment and capturing techniques to reliably isolate CTCs for molecular characterisation are particularly needed."

For further information                                                       www.angleplc.com 

SOURCE ANGLE plc

Related Links

http://www.angleplc.com